Submit a Case Submit Case Find a Neutral Search Neutral
Ryan Abbott

Ryan Abbott, M.D., Esq., FCIArb

JAMS Mediator, Arbitrator and Referee/Special Master

Case Manager
Burton King
T: 212-607-2758
F: 212-751-4099
620 Eighth Ave., 34th Floor, New York, NY 10018

Ryan Abbott is available to conduct cases virtually. JAMS is equipped to provide virtual ADR services on a variety of online platforms, including Zoom, Microsoft Teams, WebEx, and more.


Ryan Abbott, M.D., Esq., FCIArb has mediated and arbitrated disputes domestically and internationally with collectively tens of millions of dollars at stake. He has particular experience in the fields of intellectual property and health care, and offers unique expertise in such matters as biologics, pharmaceuticals, medical devices, medical and life sciences, computer technology and distributed ledger technology. Dr. Abbott divides his time between Los Angeles, California and London, England.

Dr. Abbott has served as partner at a litigation firm and general counsel of biotechnology companies. In these capacities, he has substantial ADR experience as outside and inside counsel for both claimants and respondents. He has also worked as an expert for the European Commission, the United Kingdom Parliament, the World Intellectual Property Organization (WIPO), the World Health Organization (WHO) and the United Nations Development Programme (UNDP). 

Dr. Abbott is a licensed physician and patent attorney in the United States (California and New York) and a solicitor advocate in England and Wales. He is board certified by the American Board of Legal Medicine. In addition to serving as a JAMS neutral, he is a WIPO, IACT, and United Kingdom Intellectual Property Office (UKIPO) panelist, a CEDR-accredited mediator and a Fellow of the Chartered Institute of Arbitrators (FCIArb). He has a reputation for rigorous preparation, engagement and adaptability.

Dr. Abbott is professor of law and health sciences at the University of Surrey School of Law and adjunct assistant professor of medicine at the David Geffen School of Medicine at UCLA. He is a graduate of the University of California San Diego School of Medicine and Yale Law School. Dr. Abbott lectures frequently on issues related to artificial intelligence, biotechnology, and information and communication technologies.

Representative Matters

  • Business/Commercial: Breach of contract, breach and dissolutions of partnership and joint venture agreements, licensing agreements, fraud
  • Employment: Wrongful termination, discrimination, retaliation, negligent and intentional infliction of emotional distress
  • Insurance: Coverage, bad faith, first-party claims
  • Intellectual Property: Patent, trademark, copyright, trade secret and confidential information, infringement, misappropriation, validity, license disputes, ownership, regulatory filings, technology transfer
  • Health Care: Federal/state Government and Qui Tam False Claims cases; class actions; employment and other business disputes concerning physician practice breakups; business and employment disputes between physicians and hospitals; IP dispute between university and pharma parties; employment claims by pharma sales reps; insurance coverage for malpractice, medical benefits payments and other claims; med mal cases
  • Higher Education: Conflict resolution with a variety of issues arising in the context of higher education, including internal matters related to staff and student complaints, administrative actions, allegations of inappropriate behavior and inappropriate sexual behavior, as well as external issues with universities and vendors and commercial partners. Dr. Abbott has served as visiting faculty at institutions around the world
  • Professional Liability: Negligence, billing disputes, malpractice, accounting

Completed Virtual ADR training conducted by the JAMS Institute, the training arm of JAMS.


  • Member, Global Health Law Committee of the International Law Association (ILA) 2019 – present
  • Editor, Landslide Magazine, published by the American Bar Association Section of Intellectual Property Law (ABA-IPL), 2019–Present
  • Mediation Provider, UK Intellectual Property Office (IPO), June 2019–Present
  • Academic College Reviewer, Arts and Humanities Research Council (AHRC) Peer Review College, 2017– 2020
  • Member, European Commission Expert Working Group on New Technologies Formation, 2018–2019
  • Member, Judge Paul R. Michel Intellectual Property American Inn of Court, 2014–2016
  • Board of Governors, Valley Community Healthcare, 2013–2016

Select Recent Lectures

  • 2021 American IP Law Association; Panel Moderator: AI in Drug Discovery
  • 2020 LSPN Connect; Speaker: Artificial Intelligence and Intellectual Property in the Life Sciences
  • 2019 Israel Patent Office; Speaker: Artificial Intelligence and Intellectual Property
  • 2019 Israel Patent Office, Israel Innovation Authority, WIPO; Panelist & Speaker: International Conference on Emerging Technologies and Intellectual Property—Connecting the Bits
  • 2019 Intellectual Property Office in the United Kingdom, in co-operation with the World Intellectual Property Organisation (WIPO); Speaker: Conference on the potential impact of artificial intelligence (AI) on intellectual property (IP)
  • 2019 International Conference on Emerging Technologies and Intellectual Property – Connecting the Bits; Panelist: Applications of AI - New Business and IP Strategies
  • 2019 Moho D-Day Summit; Presenter: The Future of Work
  • 2019 EUIPO: IP Mediation Conference; Presenter: The Future of Online Mediation – AI Mediators and AI Evaluative Tools
  • 2018 3rd International Convention on The Economy of Innovation, AIPPI; Panelist: Traditional Medicine—The Influence of IP on Commercial Use and Economic Aspects
  • 2018 Oxford Faculty of Law, Business Law Workshop, Inventive Machines and the Evolving Nature of Innovation
  • 2018 Office of Intellectual Property of the Ministry of Economy, Institute of Intellectual Property
    Luxembourg; Presenter: 11th Annual Luxembourg Intellectual Property Day: Artificial Intelligence and Intellectual Property Challenges
  • 2018 Stanford Law School; Presenter: We Robot Conference: Everything Is Obvious; Should Robots Pay Taxes? Tax Policy in the Age of Automation
  • 2018 King’s Transnational Law Summit; Moderator: A World of Risk: Health, Technology and the Human Life; Panelist: Us and Them: Living With Robots
  • 2018 University of Surrey; Chair: Surrey Workshop on the Regulation of AI
  • 2018 University of San Diego; Presenter: PatCon 8: The Annual Patent Conference; Everything Is Obvious
  • 2018 King’s College London; Guest Lecturer: Transnational Intellectual Property
  • 2018 ICEVOX; Presenter: Cybercrime and Security, Bitcoin and the Power of Decentralized Prediction Markets
  • 2018 WIPO/Rospatent/Skolkovo; Panelist: International Conference on Intellectual Property in the New Technological Order, International Protections for Computer-Generated Works
  • 2017 IBC Leal; Moderator and Panelist: Standards, Patents and Competition Conference, Future of Patenting for AI-Created Innovations
  • 2017 CEIPI/WIPO/INPI Lecturer: Advanced Course on Intellectual Property, Technology Transfer and Licensing
    Intellectual Property Management in Traditional Medical Knowledge
  • 2017 Leeds School of Law; Roundtable Participant: Personalized Medicine and the Law
  • 2017 CEIPI/BETA/I3PM Conference; Speaker: Intellectual Property and Digitalization: Challenges for Intellectual Property Management, Creative Computers and the Future of Patent Law
  • 2017 Florida State University; Law 7930: Global Health and Pharmaceutical Regulation, Global Regulation of Off-Label Drug Use and Traditional Medicine
  • 2017 Czech Parliament Committee on Health; Roundtable Presenter, U.S. Regulation and Legislation on Traditional Chinese Medicine


  • The Reasonable Robot: Artificial Intelligence and the Law; Cambridge University Press (2020).
  • Abbott, Ryan and Alex Sarch, Punishing Artificial Intelligence: Legal Fiction or Science Fiction, UC Davis Law Review (Forthcoming 2019)
  • “Artificial Intelligence, Big Data and Intellectual Property: Protecting Computer-Generated Works in the United Kingdom.” In Research Handbook on Intellectual Property and Digital Technologies, Edward Elgar (Tanya Aplin, ed.) (Forthcoming 2019).
  • What Crypto Exchanges, Holders Can Learn From QuadrigaCX, Law360, Feb 2019, co-author.
  • Ryan Abbott, Everything is Obvious, 66 UCLA. L. REV. 2 (2019)
  • Managing Disputes in the Life Sciences, Nature Biotechnology (2018).
  • Should Robots Pay Taxes? Tax Policy in the Age of Automation, 12 Harv. L. & Pol. Rev. 145 (2018).
  • The Reasonable Computer: Disrupting the Paradigm of Tort Liability, 86 Geo. Wash. L. Rev. 1 (2018)
  • “The Sentinel Initiative as a Cultural Commons.” In Governing Medical Research Commons, Cambridge University Press (Katherine Strandburg, et al., eds.) (2017).
  • I Think, Therefore I Invent: Creative Computers and the Future of Patent Law, 57 B.C. L. Rev. 1079 (2016).
  • Republished in part: Autonomous Machines and Their Inventions. Mitteilungen, 429-437, 2017.
  • Republished in part: Patenting the Output of Autonomously Inventive Machines. Landslide, 10 (1), 16-22, 2017.
  • “Big Data and Its Use by Artificial Intelligence.” In Big Data Is Not a Monolith, MIT Press (Hamid Ekbia, et al., eds.) (2016).
  • Evidence and Extrapolation: Mechanisms for Regulating Off-Label Uses of Drugs and Devices, 64 Duke L.J. 377 (2014).
  • Republished in part: Can Bayesian Extrapolation Improve FDA Regulation of Off-Label Uses of Drugs and Devices? FDLI's Food and Drug Policy Forum; 4(5), 1-12, 2014.
  • World Intellectual Property Organization, Documenting Traditional Medical Knowledge (2014).
  • FDA Involvement in Off-Label Use: Debate Between Richard Epstein and Ryan Abbott, 44 Sw. L. Rev. 1 (2014).
  • Redefining Medical Necessity: A Consumer-Driven Solution to the U.S. Health Care Crisis. 47 Loy. L.A. L. Rev. 943 (2014).
  • Balancing Access and Innovation in India's Shifting IP Regime, Remarks (2014). 35 Whittier Law Review 341 (2014).
  • Big Data and Pharmacovigilance: Using Healthcare Information Exchanges to Revolutionize Drug Safety, 99 Iowa L. Rev. 225 (2013).
  • Republished in part: Post-Market Drug Regulation in the Age of Big Data: What Path to the Promised Land? FDLI's Food and Drug Policy Forum, 4 (10), 1-14, 2014.
  • Medico-Legal Issues in Cardiology. Cardiol Rev. 2013 Sep-Oct; 21(5):222-8.
  • Ph.D., University of Surrey School of Law, 2020 
  • Solicitor Advocate, England and Wales, 2017–present
  • Attorney, California and New York (licensed), 2012–present    
  • Patent Attorney, United States Patent and Trademark Office, 2011–present
  • Partner; Brown, Neri, Smith & Khan, LLP; 2016–present
  • General Counsel and Medical Director; Abcentra, LLC; 2014–present
  • Of Counsel, One LLP, 2013–2016
  • Associate Professor, Southwestern Law School, 2012–2016
  • Intern Physician, Santa Clara Valley Medical Center, 2011–2012
  • M.D., University of California, San Diego, 2011
  • J.D., Yale Law School, 2011
  • Consultant, World Intellectual Property Organization, 2009–2012
  • Consultant, Medicines Transparency Alliance, 2010
  • Consultant, World Health Organization, 2008–2010
  • Consultant, UCLA Center for East-West Medicine, 2006–2010
  • Consultant, Health Research for Action, 2009
  • Summer Associate, Dewey & LeBoeuf LLP, 2009
  • Summer Intern, World Health Organization, 2008
  • M.T.O.M., Emperor’s College, 2005
  • B.S., University of California, Los Angeles, 2005
  • Foreign Language Immersion Program (Mandarin Chinese), Shanghai Jiao Tong University, Summer 2002



Practice Areas

  • Arbitration
  • Business & Commercial
  • Education Law
  • Employment Law
  • Health Care
  • Higher Education & Title IX
  • Intellectual Property
  • Life Sciences
  • Personal Injury/Torts
  • Pharmaceuticals/Mass Tort
  • Professional Liability


This page is for general information purposes.  JAMS makes no representations or warranties regarding its accuracy or completeness.  Interested persons should conduct their own research regarding information on this website before deciding to use JAMS, including investigation and research of JAMS neutrals. See More